5-14-0

In Re Application of: REIMANN et al. Art Unit: 1632 Application No.: 09/241,595 Examiner: A Beckerleg Filed: February 2, 1999 Washington, D.C. For: DELIVERY OF IMMUNOGENIC MOLECULES VIA HBSAG PARTICLES Atty.'s Docket: REIMANN=1 Date: May 3, 2001 THE COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 Sir: Transmitted herewith is a [ ] Amendment [ X] SUPPLEMENTAL RESPONSE in the above-identified application. [XX] Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed. No additional fee is required. The fee has been calculated as shown below: (Col.) (Col. 2) (Col. 3) SMALL ENTITY OTHER THAN SMALL ENTITY CLAIMS HIGHEST RATE ADDITIONAL PRESENT OR RATE **ADDITIONAL** REMAINING **EXTRA** FEE FEE **PREVIOUSLY** AFTER **EQUALS** AMENDMENT PAID TOTAL \* 30 MINUS 30 0 9 18 INDEP 4 MINUS 4 0 40 \$ 80 \$ FIRST PRESENTATION OF MULTIPLE DEP. CLAIM 135 \$ 270 ADDITIONAL FEE TOTAL \$ OR TOTAL \$ If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3. If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space. If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space. The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed. [XX] Conditional Petition for Extension of Time If any extension of time for a response is required, applicant requests that this be considered a petition therefor. [ ] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below: Small Entity Other Than Small Entity Response Filed Within Response Filed Within First [ ] 55.00 110.00 1 1 Second 195.00

[ ] Second - \$ 390.00 [ ] Third - \$ 890.00

[ ] Fourth - \$ 1390.00

Month After Time Period Set Month After Time Period Set

[ ] Less fees (\$\_\_\_\_\_) already paid for \_\_\_ month(s) extension of time on \_\_\_\_\_

Please charge my Deposit Account No. 02-4035 in the amount of \$\_\_\_\_\_

445 00

- \$ 695.00

[ ] Credit Card Payment Form, PTO-2038, is attached, authorizing payment in the amount of \$\_.

[ ] A check in the amount of \$\_\_\_\_\_ is attached (check no. ).

[XX] The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

**BROWDY AND NEIMARK** 

Attorneys for Applicant(s)

ву.

Allen C. Yun Registration No. 37,971

Facsimile: (202) 737-3528 Telephone: (202) 628-5197

1

[ ]

Fourth

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTY.'S DOCKET: REIMANN=1

In re Application of:

Jorg REIMANN et al

Art Unit: 1632

Appln. No.: 09/241,595

Confirmation No.: 8928

Filed: February 2, 1999

For: DELIVERY OF IMMUNOGENIC

MOLECULES VIA HbsAg
PARTICLES

Art Unit: 1632

Mashington, D.C.

May 3, 2001

May 3, 2001

## SUPPLEMENTAL RESPONSE

Honorable Commissioner for Patents Washington, D.C. 20231

## Sir:

Supplemental to the response filed March 20, 2001, on which applicants continue to primarily rely, attached hereto are copies of the articles cited in the response filed March 20, 2001. The attached Schirmbeck et al., International Immunology 11(7):1093-1102 (1999), and Böhm et al., Vaccine 16:949-954 (1998), articles were misidentified as Reimann et al. (even though J. Reimann is a co-author) on pages 4 and 7 of the response filed March 20, 2001.

The Ogg et al., <u>Science</u> 279:2103-2106 (1998), article attached hereto was inadvertently not cited on page 10 with the other HIV-related publications in the response filed March 20, 2001.

İn re' of Appln. N 09/241,595

Favorable consideration and allowance are earnestly urged.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C. Attorneys for Applicant(s)

Ву

FOREST MEDICAL STATE

Allen C. Yun

Registration No. 37,971

ACY:pr

Telephone No.: (202) 628-5197 Facsimile No.: (202) 737-3528

F:\,C\cohn\Reimann1\Pto\supplemental response.wpd